Loss of HIPK2 Causes Galectin-3 Overexpression in Thyroid Cancer
Author Information
Author(s): Lavra Luca, Rinaldo Cinzia, Ulivieri Alessandra, Luciani Emidio, Fidanza Paolo, Giacomelli Laura, Bellotti Carlo, Ricci Alberto, Trovato Maria, Soddu Silvia, Bartolazzi Armando, Sciacchitano Salvatore
Primary Institution: Research Center, St. Pietro Fatebenefratelli Hospital, Rome, Italy
Hypothesis
Is HIPK2 deficiency responsible for Galectin-3 overexpression in well-differentiated thyroid carcinomas?
Conclusion
The study found that loss of HIPK2 expression in thyroid cancers explains the overexpression of Galectin-3, suggesting HIPK2 as a potential tumor suppressor gene.
Supporting Evidence
- HIPK2 protein levels were high in all follicular hyperplasias analyzed.
- 91.7% of papillary thyroid carcinomas showed undetectable HIPK2.
- HIPK2 mRNA levels were significantly lower in PTCs compared to follicular hyperplasia.
- Loss of heterozygosity at the HIPK2 locus was found in 37.5% of PTCs.
Takeaway
When a protein called HIPK2 is missing in thyroid cancer, another protein called Galectin-3 gets too high, which can make the cancer worse.
Methodology
The study analyzed HIPK2 protein and mRNA levels in thyroid tissue samples and performed in vitro experiments to manipulate HIPK2 expression.
Limitations
The study does not explore all potential mechanisms of HIPK2 inactivation in thyroid cancers.
Participant Demographics
The study included patients with various types of thyroid lesions, including follicular hyperplasia and different types of thyroid carcinomas.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website